MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021.
Recent Business Highlights
• Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year
• Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period
• Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period
• Received FDA 510(k) Clearance of the TearCare® System for treatment of Meibomian Gland Disease (MGD), the leading cause of Dry Eye Disease
• Clinical data from the prospective, multicenter GEMINI clinical trial was published…